60 Degrees Pharmaceuticals reported a net loss of $6.9 million for the nine months ended September 30, 2026, compared to $5.9 million in the prior year period. The company's cash position decreased significantly to $306,191, and management expressed concerns regarding its ability to continue as a going concern without additional financing.
60 Degrees Pharmaceuticals entered into inducement agreements with warrant holders to exercise existing warrants for 584,492 shares at a reduced price of $0.90 per share. In exchange for the cash exercise, the company will issue new unregistered warrants for up to 1,168,984 shares. The company expects to receive gross proceeds of approximately $526,042 to be used for working capital and general corporate purposes.
60 Degrees Pharmaceuticals announced positive clinical and molecular results from the first five patients in its expanded access study of tafenoquine-containing regimens for relapsing babesiosis. All five patients (100%) reported significant clinical improvement and tested negative for Babesia on conventional PCR tests, supporting the potential efficacy of the combination therapy in immunosuppressed patients.
60 Degrees Pharmaceuticals updated its investor presentation for use in meetings with investors and analysts, specifically highlighting progress for Tafenoquine in treating Babesiosis. The presentation was featured at the 2026 ILADS Annual Scientific Conference and outlines a regulatory objective for a potential sNDA submission in 2027.
60 Degrees Pharmaceuticals updated its investor presentation and held a webinar to discuss interim data from its clinical study of tafenoquine for severe babesiosis. The presentation covers clinical context, DSMB feedback from the hospital study, and the regulatory path forward for the treatment.